This page contains promotional content about Trimbow® (beclometasone / formoterol / glycopyrronium)

Step up with real confidence

Step up with real confidence

Now supported by the TriMaximize real-world study,* Trimbow is the only extrafine formulation single inhaler triple therapy (SITT) licensed as both a medium and high dose in adult asthma.1–4

Watch the video Learn more

*TriMaximize was a multicentre, prospective, non-interventional, observational study conducted across 8 countries in 1445 adult patients with moderate-to-severe asthma in a real-world setting.1

The reality of uncontrolled asthma

The reality of uncontrolled asthma

30–50% of adult asthma patients on ICS/LABA therapy remain uncontrolled.5–8 These patients may experience significant symptoms and limitations in daily activities.1,9

Learn more
TriMaximize and Trimbow

TriMaximize and Trimbow

Trimbow’s clinical benefits, now reinforced by TriMaximize, go beyond just symptom control.1 In addition, it demonstrated a safety profile comparable with its SPCs.1–3

Learn more Safety profile